Knowledge and Evaluation Research Unit in Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
BMJ Open Diabetes Res Care. 2021 Apr;9(1). doi: 10.1136/bmjdrc-2020-001906.
Observational studies constitute an important evidence base for hypoglycemia in diabetes management. This requires consistent and reliable ascertainment and reporting methodology, particularly in studies of type 2 diabetes where hypoglycemia risk is heterogeneous. Therefore, we aimed to examine the definitions of hypoglycemia used by observational studies of patients with type 2 diabetes.
We conducted a meta-epidemiological review of observational studies reporting on hypoglycemia or evaluating glucose-lowering medications in adults with type 2 diabetes. MEDLINE and Google Scholar were searched from January 1970 to May 2018. The definitions of non-severe, severe and nocturnal hypoglycemia were examined.
We reviewed 243 studies: 47.7% reported on non-severe hypoglycemia, 77.8% on severe hypoglycemia and 16.9% on nocturnal hypoglycemia; 5.8% did not specify. Among 116 studies reporting non-severe hypoglycemia, 18.1% provided no definition, 23.3% used glucose values, 38.8% relied on patient-reported symptoms, 17.2% accepted either glucose values or patient-reported symptoms and 2.6% relied on International Classification of Disease (ICD) codes. Among 189 studies reporting severe hypoglycemia, 11.1% provided no definition, 53.4% required symptoms needing assistance, 3.7% relied on glucose values, 14.8% relied on ICD codes, 2.6% relied on ICD codes or glucose values and 15.9% required both symptoms needing assistance and glucose values. Overall, 38.2% of non-severe and 67.7% of severe hypoglycemia definitions were consistent with the International Hypoglycemia Study Group.
The marked heterogeneity in how hypoglycemia is defined in observational studies may contribute to the inadequate understanding and correction of hypoglycemia risk factors among patients with type 2 diabetes.
观察性研究构成了糖尿病管理中低血糖的重要证据基础。这需要一致和可靠的确定和报告方法,特别是在 2 型糖尿病研究中,低血糖风险具有异质性。因此,我们旨在研究 2 型糖尿病患者观察性研究中使用的低血糖定义。
我们对 2018 年 5 月前从 1970 年 1 月至 2018 年 5 月在 MEDLINE 和 Google Scholar 上搜索的报告 2 型糖尿病患者低血糖或评估降糖药物的观察性研究进行了荟萃分析。检查了非严重、严重和夜间低血糖的定义。
我们回顾了 243 项研究:47.7%报告非严重低血糖,77.8%报告严重低血糖,16.9%报告夜间低血糖;5.8%未指定。在 116 项报告非严重低血糖的研究中,18.1%未提供定义,23.3%使用血糖值,38.8%依赖于患者报告的症状,17.2%接受血糖值或患者报告的症状,2.6%依赖于国际疾病分类(ICD)代码。在 189 项报告严重低血糖的研究中,11.1%未提供定义,53.4%需要有症状需要帮助,3.7%依赖于血糖值,14.8%依赖于 ICD 代码,2.6%依赖于 ICD 代码或血糖值,15.9%需要症状需要帮助和血糖值。总体而言,38.2%的非严重低血糖和 67.7%的严重低血糖定义与国际低血糖研究小组一致。
观察性研究中低血糖定义的明显异质性可能导致 2 型糖尿病患者对低血糖风险因素的认识不足和纠正不足。